JP2015527975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527975A5 JP2015527975A5 JP2015517392A JP2015517392A JP2015527975A5 JP 2015527975 A5 JP2015527975 A5 JP 2015527975A5 JP 2015517392 A JP2015517392 A JP 2015517392A JP 2015517392 A JP2015517392 A JP 2015517392A JP 2015527975 A5 JP2015527975 A5 JP 2015527975A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- oxygen
- reservoir
- stable composition
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 77
- 239000000203 mixture Substances 0.000 claims description 62
- 150000004770 chalcogenides Chemical class 0.000 claims description 27
- 229910052798 chalcogen Inorganic materials 0.000 claims description 24
- 150000001787 chalcogens Chemical class 0.000 claims description 23
- 239000011669 selenium Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 17
- 239000003638 chemical reducing agent Substances 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 239000004698 Polyethylene Substances 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 229920001684 low density polyethylene Polymers 0.000 claims description 10
- 239000004702 low-density polyethylene Substances 0.000 claims description 10
- 229920000573 polyethylene Polymers 0.000 claims description 10
- 239000011118 polyvinyl acetate Substances 0.000 claims description 10
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
- 229920002620 polyvinyl fluoride Polymers 0.000 claims description 10
- 229910052711 selenium Inorganic materials 0.000 claims description 9
- 229940091258 selenium supplement Drugs 0.000 claims description 9
- 229920008790 Amorphous Polyethylene terephthalate Polymers 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 7
- 239000004800 polyvinyl chloride Substances 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- -1 polyethylene Polymers 0.000 claims description 6
- 239000012279 sodium borohydride Substances 0.000 claims description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 244000043261 Hevea brasiliensis Species 0.000 claims description 5
- 229920002292 Nylon 6 Polymers 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 239000004715 ethylene vinyl alcohol Substances 0.000 claims description 5
- 229920003052 natural elastomer Polymers 0.000 claims description 5
- 229920001194 natural rubber Polymers 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 5
- 239000004417 polycarbonate Substances 0.000 claims description 5
- 229920000515 polycarbonate Polymers 0.000 claims description 5
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 229920001971 elastomer Polymers 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 229920002379 silicone rubber Polymers 0.000 claims description 4
- 239000004945 silicone rubber Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 206010061216 Infarction Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000007574 infarction Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 229940000207 selenious acid Drugs 0.000 claims description 3
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 2
- NLZOGIZKBBJWPB-UHFFFAOYSA-N [Na].[SeH2] Chemical compound [Na].[SeH2] NLZOGIZKBBJWPB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000012298 atmosphere Substances 0.000 claims description 2
- 210000004351 coronary vessel Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 229960001471 sodium selenite Drugs 0.000 claims description 2
- 239000011781 sodium selenite Substances 0.000 claims description 2
- 235000015921 sodium selenite Nutrition 0.000 claims description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 claims description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 229910052714 tellurium Inorganic materials 0.000 claims 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229910000058 selane Inorganic materials 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659311P | 2012-06-13 | 2012-06-13 | |
| US61/659,311 | 2012-06-13 | ||
| US201361798043P | 2013-03-15 | 2013-03-15 | |
| US61/798,043 | 2013-03-15 | ||
| PCT/US2013/045395 WO2013188528A1 (en) | 2012-06-13 | 2013-06-12 | Compositions comprising chalcogenides and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015527975A JP2015527975A (ja) | 2015-09-24 |
| JP2015527975A5 true JP2015527975A5 (enExample) | 2016-05-26 |
Family
ID=49758688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517392A Pending JP2015527975A (ja) | 2012-06-13 | 2013-06-12 | カルコゲニドを含む組成物および関連方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150290240A1 (enExample) |
| EP (1) | EP2861718A4 (enExample) |
| JP (1) | JP2015527975A (enExample) |
| KR (1) | KR20150021509A (enExample) |
| CN (1) | CN104471058A (enExample) |
| AU (1) | AU2013274325A1 (enExample) |
| BR (1) | BR112014030992A2 (enExample) |
| CA (1) | CA2875212A1 (enExample) |
| HK (1) | HK1209782A1 (enExample) |
| IN (1) | IN2014MN02391A (enExample) |
| MX (1) | MX2014014524A (enExample) |
| RU (1) | RU2015100257A (enExample) |
| WO (1) | WO2013188528A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386702B (es) * | 2014-02-10 | 2025-03-19 | Fred Hutchinson Cancer Center | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. |
| CN109650353A (zh) * | 2019-01-14 | 2019-04-19 | 成都中建材光电材料有限公司 | 一种高纯二硫化硒的制备方法 |
| US20230256003A1 (en) * | 2020-06-25 | 2023-08-17 | Industry-University Cooperation Foundation Hanyang University Erica Campus | Pharmaceutical composition for preventing or treating sepsis containing functionalized transition metal dichalcogenide |
| CN114471430B (zh) * | 2022-02-07 | 2024-01-02 | 天津大学 | 一种连续生产碱金属硫化物的装置及其合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1499852A (en) * | 1975-03-04 | 1978-02-01 | Smith & Nephew Pharma | Packaging |
| US5208336A (en) * | 1990-10-19 | 1993-05-04 | Sterling Drug Inc. | Selenomerocyanines and processes for preparation and methods of use and compositions thereof |
| US5616214A (en) * | 1995-09-12 | 1997-04-01 | Pulp And Paper Research Institute Of Canada | Determination of sodium sulfide and sulfidity in green liquors and smelt solutions |
| PE20001435A1 (es) * | 1998-11-16 | 2000-12-14 | Paques Bio Syst Bv | Proceso para la produccion de sulfuro de hidrogeno a partir de azufre en su condicion elemental y uso del mismo en la recuperacion de metales pesados |
| US6579705B2 (en) * | 2001-04-04 | 2003-06-17 | Consortium Fur Elektrochemische Industrie Gmbh | Process for preparing non-proteinogenic L-amino acids |
| EP1479725B1 (en) * | 2002-02-26 | 2014-05-14 | Kuraray Co., Ltd. | Resin composition and multi-layer structures |
| EP1753428A4 (en) * | 2004-05-14 | 2010-09-15 | Abbott Lab | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS |
| WO2007124447A2 (en) * | 2006-04-20 | 2007-11-01 | Fred Hutchinson Cancer Research Center | Use of chalcogenides for treating shock and other adverse conditions |
| JP5303465B2 (ja) * | 2006-10-05 | 2013-10-02 | イカリア， インコーポレイテッド | 液体カルコゲナイド組成物ならびにそれを製造および使用する方法 |
| JP5083753B2 (ja) * | 2007-02-26 | 2012-11-28 | 独立行政法人理化学研究所 | ４，５−ジメチル−［１，３］ジセレノール−２−セロンの新規製造方法 |
| JP4028588B2 (ja) * | 2007-04-27 | 2007-12-26 | 政弘 井筒 | リグノセルロース系バイオマスの利用方法 |
| RU2015109165A (ru) * | 2008-03-06 | 2015-11-10 | Анакор Фармасьютикалз, Инк. | Борсодержащие малые молекулы в качестве противовоспалительных агентов |
-
2013
- 2013-06-12 CN CN201380031213.4A patent/CN104471058A/zh active Pending
- 2013-06-12 IN IN2391MUN2014 patent/IN2014MN02391A/en unknown
- 2013-06-12 KR KR20147033920A patent/KR20150021509A/ko not_active Withdrawn
- 2013-06-12 CA CA2875212A patent/CA2875212A1/en not_active Abandoned
- 2013-06-12 BR BR112014030992A patent/BR112014030992A2/pt not_active IP Right Cessation
- 2013-06-12 RU RU2015100257A patent/RU2015100257A/ru not_active Application Discontinuation
- 2013-06-12 JP JP2015517392A patent/JP2015527975A/ja active Pending
- 2013-06-12 WO PCT/US2013/045395 patent/WO2013188528A1/en not_active Ceased
- 2013-06-12 EP EP13805096.8A patent/EP2861718A4/en not_active Withdrawn
- 2013-06-12 AU AU2013274325A patent/AU2013274325A1/en not_active Abandoned
- 2013-06-12 US US14/406,859 patent/US20150290240A1/en not_active Abandoned
- 2013-06-12 MX MX2014014524A patent/MX2014014524A/es unknown
- 2013-06-12 HK HK15110369.5A patent/HK1209782A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527975A5 (enExample) | ||
| WO2014057220A1 (fr) | Procédé pour conserver le sang placentaire | |
| CN102349500A (zh) | 一种间充质干细胞自体保存液 | |
| ES2906577T3 (es) | Sistema de bolsas múltiples para la preparación de hemoderivados | |
| RU2015100257A (ru) | Композиции, содержащие халькогениды, и связанные способы | |
| Keipert et al. | Effects of partial and total isovolemic exchange transfusion in fully conscious rats using pyridoxylated polyhemoglobin solution as a colloidal oxygen-delivering blood replacement fluid | |
| CN108378021A (zh) | 一种淋巴细胞冷藏保存体系 | |
| JP2018531905A5 (enExample) | ||
| CN104971049B (zh) | 一种含有福沙匹坦的冻干制剂及其制备方法 | |
| JP4041171B2 (ja) | 血小板保存液 | |
| JP5328004B2 (ja) | 膵島保存方法、膵島保存用容器及び膵島移植用キット | |
| CN102524242A (zh) | 一种器官保存液的制备方法 | |
| CN208114809U (zh) | 一种带开启边的液液双室输液用袋 | |
| CN205145225U (zh) | 一种多用途血液细胞采集分离套装 | |
| Högman et al. | Shall red cell units stand upright, lie flat or be mixed during storage? In vitro studies of red cells collected in 0.5 CPD and stored in RAS2 (Erythrosol®) | |
| CN102240261A (zh) | 一种葡甘露聚糖注射液的制备方法及其医学用途 | |
| JPWO2021201029A5 (enExample) | ||
| Thirumala et al. | A cryopreservation system for direct clinical use of MSC | |
| Morrison | Platelet transfusion: a brief review of practical aspects | |
| Corcos | Toward a universal treatment for cancer: cell inflation assisted chemotherapy | |
| CN220712658U (zh) | 冻存袋 | |
| CN102429860A (zh) | 一种双腔袋包装的硫酸头孢匹罗注射液及其制备方法 | |
| CN202784021U (zh) | 血袋盛放筐 | |
| CN102429863A (zh) | 一种双腔袋包装的阿奇霉素注射液及其制备方法 | |
| JPWO2020264161A5 (enExample) |